https://scholars.lib.ntu.edu.tw/handle/123456789/628837
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Tsuboi, Masahiro | en_US |
dc.contributor.author | Goldman, Jonathan W | en_US |
dc.contributor.author | Wu, Yi-Long | en_US |
dc.contributor.author | Johnson, Melissa L | en_US |
dc.contributor.author | Paz-Ares, Luis | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | Besse, Benjamin | en_US |
dc.contributor.author | Su, Weiji | en_US |
dc.contributor.author | Chao, Bo H | en_US |
dc.contributor.author | Drilon, Alexander | en_US |
dc.date.accessioned | 2023-03-02T01:56:12Z | - |
dc.date.available | 2023-03-02T01:56:12Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/628837 | - |
dc.description.abstract | Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment-naive advanced/metastatic RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, randomized, double-blind, phase III trial evaluating selpercatinib versus placebo in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RET fusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system. | en_US |
dc.language.iso | en | en_US |
dc.publisher | FUTURE MEDICINE LTD | en_US |
dc.relation.ispartof | Future oncology (London, England) | en_US |
dc.subject | RET fusion-positive; RET kinase inhibitor; RET rearrangement; adjuvant therapy; early stage; non-small-cell lung cancer; phase III trial; selpercatinib; stage IB; stage II; stage IIIA; targeted therapy | en_US |
dc.title | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | en_US |
dc.type | journal article | en |
dc.type | review | en_US |
dc.identifier.doi | 10.2217/fon-2022-0656 | - |
dc.identifier.pmid | 35950566 | - |
dc.identifier.scopus | 2-s2.0-85139880560 | - |
dc.identifier.isi | WOS:000838720700001 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85139880560 | - |
dc.relation.pages | 3133 | en_US |
dc.relation.journalvolume | 18 | en_US |
dc.relation.journalissue | 28 | en_US |
dc.relation.pageend | 3141 | en_US |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。